Information Provided By: 
Fly News Breaks for February 6, 2020
BHVN
Feb 6, 2020 | 05:25 EDT
Mizuho analyst Vamil Divan last night initiated coverage of Biohaven Pharmaceutical with a Buy rating and $62 price target. The analyst believes rimegepant has benefits for migraine headaches, including lasting longer and having fewer side effects than competitors. Divan says that while Biohaven shares have upside based on continued rimegepant success alone, he's also "intrigued" by the progress the company is making with troriluzole, which is now in four different Phase 2/3 trials for various neurological conditions.
News For BHVN From the Last 2 Days
BHVN
Apr 23, 2024 | 09:00 EDT
UBS raised the firm's price target on Biohaven to $60 from $59 and keeps a Buy rating on the shares after hosting meetings with management. The stock's 28% selloff since April 15 represents an "attractive opportunity," the analyst tells investors in a research note. The firm sees an attractive risk/reward into the Phase 1 degrader data on May 29. A key opinion leader viewed Biohaven's degrader platform as an elegant approach to various disease modalities, says UBS. The firm says the stock's bear case is overdone.
